Kamada Ltd. (KMDA:NASDAQ) closed at $8.09 on November 13, 2026, down 0.49% on the day. The stock trades 13.5% below its 52-week high of $9.35 and 22.6% above its 52-week low of $6.60. Over the past year, it gained 15.7%. Kamada Ltd. is part of the Health Care sector (Major Pharmaceuticals).
In 252 trading sessions since November 13, 2025, KMDA closed higher on 115 days (46%). Its best day was January 26, 2026 (+8.08%) and its worst was November 5, 2026 (-7.41%). It never moved 10% or more in a single session. It opened at least 5% above the previous day's high 2 times.
Kamada Ltd. develops, produces, and markets specialty plasma-derived protein therapeutics. It operates in two segments, Proprietary Products and Distribution. Its respiratory disease products, including Glassia used in augmentation therapy for patients with emphysema secondary to congenital alpha-1 antitrypsin deficiency; and Bramitob to manage chronic pulmonary infection. The company's immunoglobulin products include KamRAB for prophylaxis against rabies infection; KamRho(D)IM to treat prophylaxis of hemolytic disease of newborns; KamRho(D)IV for immune thermobocytopunic purpura; Snake bite antiserum to treat snake bites by the vipera palaestinae and echis coloratus; IVIG 5% for various immunodeficiency-related conditions; Hepatect CP, a hepatitis B immunoglobulin; Megalotect, a CMV immunoglobulin; and Varitect, a varicella zoster immunoglobulin. In addition, it provides critical care products, such as Heparin sodium injection to treat thrombo-embolic disorders; and Albumin for maintenance of proper level in the patient's blood plasma. Further, the company offers Heparin Lock Flush to maintain patency of indwelling IV catheter; Human Transferrin for diagnostic assays and cell cult...
Find more stocks like KMDA with the Spikes, Gaps, Breakouts and Performance Tracker scanners.
Based on end-of-day data. For information only, not investment advice.